Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app

#digitalhealth #mentalhealth #BoehringerIngelheim #DTx #schizophrenia #phase3clinicaltrial #digitaltherapeutics #smartphonebasedapp #CT155app #ClickTherapeutics #CONVOKEstudy #CONVOKE #prescriptiondigitaltherapeutic #CAINSMAP #CT155 #antipsychotics #breakthroughdevicestatus
zurl.co/cndtD